Dicerna Pharmaceuticals Inc (DRNA) was Reiterated by Chardan Capital Markets to “Neutral” while Lowering the Price Target of the company shares to $ 3.50 from a previous price target of $4 . Chardan Capital Markets advised their investors in a research report released on Aug 15, 2016.
Many Wall Street Analysts have commented on Dicerna Pharmaceuticals Inc. Shares were Reiterated by Chardan Capital Markets on Aug 8, 2016 to “Neutral” and Lowered the Price Target to $ 3.50 from a previous price target of $4 .Shares were Reiterated by Stifel on Jun 30, 2016 to “Buy” and Lowered the Price Target to $ 13 from a previous price target of $16 .Shares were Reiterated by Chardan Capital Markets on Jun 30, 2016 to “Neutral” and Lowered the Price Target to $ 4 from a previous price target of $5 .
Dicerna Pharmaceuticals Inc opened for trading at $3.2993 and hit $3.48 on the upside on Friday, eventually ending the session at $3.45, with a gain of 4.23% or 0.14 points. The heightened volatility saw the trading volume jump to 3,80,574 shares. Company has a market cap of $72 M.
Dicerna Pharmaceuticals Inc. (Dicerna) is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNA interference (RNAi) technology platform to build a pipeline in these therapeutic areas. The Company is in collaboration with two companies for oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co. Ltd. (KHK). Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1) Additional Liver Targets DCR-MYC for MYC-related cancers and KRAS Program. Dicerna’s discovery approach is based on double-stranded RNA molecules called Dicer Substrate siRNA (DsiRNA).